Anecdotal use of convalescent plasma: an option in severe COVID-19 patients

AUTHOR(s) : Dutta Manaswi, Mahanta Putul
DOI No. : 10.31741/ijhrmlp.v6.i2.2020.16

Originating from Wuhan, China the Coronavirus Disease(COVID-19) has now achieved proportions of a massive pandemic. The threat posed by the disease has mutilated health systems across the world. Time and again, researchers have strived to discover a definite cure but with no success so far. The time required to propound a vaccine might take a year or more. The healthcare delivery system has employed antivirals, supportive care, and isolation strategies over the months. In this dire scenario, convalescent plasma therapy(CPT) could be a harbinger of hope, given its success in the previous influenza-like illnesses. Though this disease has salient features quite different from classical influenza, yet the symptoms are roughly similar. Plasma therapy experiments conducted throughout different countries yielded variable results, yet not negative. Patient factors, the severity of the disease, and the strain of the virus could have a drastic effect in the course of therapy. India, too, has conducted some successful passive antibody transfusions, but the wide-scale result is not precise. The potential merits can be obscure presently. We have to consider the willingness of the donors at the same time. CPT has emerged to be feasible and might prove to be efficacious in the long run.
Keywords: Plasma transfusion; passive immunity; passive antibody transfer; SARS-CoV-2; pandemic.

Registered Office Address:
House No: One, Karmabir Bordoloi Path, Wireless,
Rukmini Nagar, Dispur-06, Assam, India

Mobile: 09435017802
IJHRMLP is an open-access journal, and the articles published are instantly available to read and use again. The published articles thus can be downloaded, shared, and reused without restriction if the contributing original authors are appropriately cited. Author(s) retain the copyright of their article, with articles licensed to AHRME and the journal following the Creative Commons Attribution License (CC-BY).
Maintain By Prism Infosys